globalagliatin
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01247363)
Timeline
Indications
Mechanism of action
- GlucokinaseACTIVATOR
GCK activator
- Hexokinase type IVACTIVATOR
GCK activator
Chemistry & pharmacology
Loading structure…
SMILES
Cl.O=C(Nc1ncc(SCCN2CCCC2)s1)[C@]1(c2ccc(S(=O)(=O)C3CC3)cc2)C[C@H]1C1CCCCC1- Mol. weight
- 596.28 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095182 ↗
Also known as
- globalagliatin hydrochloride
- ly2608204
- ly2608204
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04907019 | Phase 1 | Jul 1, 2021 | Yabao Pharmaceutical Group |
| NCT04217291 | Phase 2 | Dec 1, 2019 | People's Liberation Army of China, Yabao Pharmaceutical Group |
| NCT03414892 | Phase 1 | Feb 24, 2018 | Yabao Pharmaceutical Group |
| NCT03171623 | Phase 1 | Apr 5, 2017 | Yabao Pharmaceutical Group |
| NCT01408095 | Phase 2 | Sep 1, 2011 | Eli Lilly |
| NCT01313286 | Phase 1 | Mar 1, 2011 | Eli Lilly |
| NCT01247363 | Phase 1 | Nov 1, 2010 | Eli Lilly |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yabao Pharmaceutical Group | For profit | 4 | 4 | 2 | 2017 |
| Eli Lilly | For profit | 3 | 3 | 2 | 2010 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1